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Japanese  
Encephalitis in Hill 
and Mountain  
Districts, Nepal
To  the  Editor:  Nepal,  a  land-
locked  country  in  Southeast  Asia 
with  an  estimated  population  of  27 
million,  is  divided  administratively 
into 5 regions; 75 districts comprise 
3 ecological zones that run from east 
to west. Altitude increases from south 
to north: the 20-district Terai plains in 
the south, the hill region in the center 
with  39  districts,  and  the  16-district 
mountain regions in the north. Japa-
nese  encephalitis  (JE)  is  seasonally 
endemic  to  the  Terai  region,  which 
borders  the  northern  India  states  of 
Uttar Pradesh and Bihar. The first out-
break of JE in Nepal was reported in 
1978 from the Terai district of Rupen-
dehi (1). Since then, JE infection has 
been reported in animal reservoirs and 
in humans throughout the Terai region 
(1–5). Although few publications de-
scribe the presence of JE outside the 
Terai, an outbreak of JE in Kathmandu 
valley in the hill region was confirmed 
in 1997 (6), and a 2006 study reported 
JE  endemicity  in  Kathmandu Valley 
(7).  In  recent  years,  the  Ministry  of 
Health  and  Population  in  Nepal  has 
introduced  public  health  interven-
tions,  including  mass  immunization 
campaigns, for JE prevention in these 
known JE-endemic areas.
JE  cases  are  captured  through 
acute  encephalitis  syndrome  (AES) 
surveillance conducted by the govern-
ment of Nepal, with support from the 
World  Health  Organization  (WHO), 
through a national sentinel surveillance 
network. From 2004 through 2006, a 
total  of  108  laboratory-confirmed  JE 
cases were reported from hill or moun-
tain  districts  (excluding  Kathmandu 
Valley). However, travel histories for 
case-patients  were  not  available  for 
these years to determine the origin of 
JE infection. We conducted a study to 
provide evidence of JE endemicity in 
hill  and  mountain  districts  of  Nepal 
(excluding Kathmandu Valley). 
Laboratory-confirmed  JE  case-
patients  identified  in  2007  who  re-
ported  residence  in  1  of  the  52  hill 
or  mountain  districts,  excluding  the 
3  hill  districts  of  the  Kathmandu 
Valley, were followed up by surveil-
lance  medical  officers.  All  patients 
(or next of kin if the patient was de-
ceased  or  unavailable)  were  visited 
at  home  or  contacted  by  telephone 
to confirm their residence and travel 
history during the 30 days before the 
onset of symptoms. Data and sample 
collection  procedures  and  laboratory 
methods used for JE diagnosis were 
as previously reported by Partridge et 
al. (7). Patients were identified by the 
AES  surveillance system  if  patients’ 
symptoms met the case definition for 
AES  adopted from WHO  guidelines 
(www.who.int/vaccines-documents/
DocsPDF06/843.pdf), i.e., acute onset 
of fever and a change in mental status 
(e.g., confusion, disorientation, coma, 
or inability to talk); or if the patient 
experienced a new onset of seizures 
(excluding simple febrile seizures) or 
was identified as having AES, JE, or 
viral encephalitis. The study popula-
tion included any person of any age 
who reported being a resident of 1 of 
the 52 hill or mountain districts (ex-
cluding Kathmandu Valley), who had 
been seen at any AES reporting site 
from January 1 through December 31, 
2007, and who had been confirmed to 
have JE antibody by immunoglobulin 
M capture ELISA on a serum or cere-
brospinal fluid (CSF) specimen.
In 2007, a total of 360 AES cases 
were reported from 40 hill or moun-
tain districts. Of the 344 reported AES 
cases  for  which  diagnostic  samples 
were obtained, 90 (26%) were labora-
tory confirmed as JE from 21 hill and 
3  mountain  districts. Among  labora-
tory confirmed JE cases, CSF samples 
were collected from 13 (14%) patients 
and serum samples from 77 (86%) pa-
tients (Table). The largest number of 
AES and laboratory-confirmed JE cas-
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es were reported during the monsoon 
months of August (23 cases) and Sep-
tember (33 cases). The higher propor-
tions of cases in male patients and in 
those <15 years of age are consistent 
with the literature (3,8,9).
Although most JE cases in Nepal 
occur in the lowland plains Terai re-
gion bordering India, our findings pro-
vide evidence that JE virus is also a 
cause of acute encephalitis in hill and 
mountain districts. This finding is con-
sistent with the report of JE endemic-
ity in the Kathmandu Valley, which is 
located in the hill region (7). Although 
the presence of both JE vectors and 
amplifying hosts has been confirmed 
in the hill region (10), additional stud-
ies are needed in high-altitude moun-
tain districts to confirm the presence 
of environmental and ecological con-
ditions that promote JE virus transmis-
sion. The national JE prevention and 
control  program  has  focused  on  the 
Terai region and, more recently, on the 
Kathmandu  Valley.  However,  results 
from our study suggest that Nepal may 
also have to consider the existence of 
JE in hill and mountain districts when 
developing future JE prevention and 
control programs. In addition, immu-
nization against JE should be recom-
mended for tourists to Nepal, even for 
those only planning to trek in the hills 
and mountains.
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Table. Characteristics of Japanese encephalitis case-patients, hill and mountain 
districts (excluding Kathmandu Valley), Nepal, 2007 
Characteristic No. (%) case-patients 
Age, y*  
   <1  6 (7) 
   1–14  67 (74) 
>15 71 (19)
Sex 
    M  59 (66) 
    F  31 (34) 
Death associated with Japanese encephalitis  5 (6) 
Specimen type collected 
    Serum  77 (86) 
    Cerebrospinal fluid  13 (14) 
History of travel outside district of residence† 
     No  84 (94) 
     Yes  3 (3) 
     Unknown  3 (3) 
*Range 4 mo–79 y. 
†During the 30 days before onset of symptoms. 
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